OSTEOPOROSIS-MANAGEMENT (SERM)

SUMMARY

SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM)
1. Raloxifene (trade name Evista) is a selective estrogen receptor modulator. Inhibits osteoclast recruitment.

2. Indications: for prevention and treatment of osteoporosis in post-menopausal women unable to take estrogen due to side effects or increased risk of breast cancer.

3. Side effects: hot flashes, increased risk of DVT.

4. Dosage: 60mg per day.

Reference(s)

Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].